Fig. 3
Ex vivo and in vitro stimulated (IVS) levels of CMV-specific IFN-γ producing T cells in AAD patients and controls. IFN-γ ELISpot was used to determine the amount of CMV-specific T cells in PBMC from HLA-A2 or HLA-B8 patients or healthy controls stimulated with HLA-restricted CMV peptide (1 µg/mL) for 24 h (ex vivo) or expanded for 13 days, and then then re-stimulated with CMV peptide for 24 h (in vitro stimulated). The results are displayed as means of triplicates of spot forming units (SFUs) per 1 × 106 PBMCs (a). The same data are also shown grouped into HLA-B8 (b) and HLA-A2 (c) positive patients (b n = ex v. 9, IVS 8, c n = ex v. 6, IVS 4) and controls (b n = ex v. 10, IVS 10, c n = ex v. 6, IVS 4). Non-parametric Mann–Whitney U test was used to test for statistical differences between patients and controls, but none were found. The bars display the mean for the whole group